We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+64.47%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.47B
AUM Growth
-$332M
Cap. Flow
-$269M
Cap. Flow %
-10.92%
Top 10 Hldgs %
58.61%
Holding
50
New
6
Increased
9
Reduced
9
Closed
4
Avg Time Held
12.7 quarters
Top 10 Avg Time Held
4.9 quarters
Top 20 Avg Time Held
7.6 quarters

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$42.3M
2
CDTX icon
Cidara Therapeutics
CDTX
+$40.1M
3
ABVX icon
Abivax
ABVX
+$34.2M
4
GPCR icon
Structure Therapeutics
GPCR
+$28.5M
5
STOK icon
Stoke Therapeutics
STOK
+$28.4M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$136M
2
CELC icon
Celcuity
CELC
+$112M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$80.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$75.6M
5
RVMD icon
Revolution Medicines
RVMD
+$39.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Miscellaneous 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KYMR icon
1
Kymera Therapeutics
KYMR
$8.87B
$311M 12.63%
5,502,710
– –
2020 Q3
20 quarters
RVMD icon
2
Revolution Medicines
RVMD
$40.4B
$186M 7.52%
3,974,913
-1,007,471
-20% -$39.4M
2020 Q1
22 quarters
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.96B
$170M 6.9%
2,560,916
-650,125
-20% -$37M
2023 Q1
10 quarters
MLTX icon
4
MoonLake Immunotherapeutics
MLTX
$886M
$142M 5.74%
19,751,284
– –
2022 Q2
13 quarters
CDTX icon
5
DELISTED
Cidara Therapeutics
CDTX
$135M 5.49%
1,414,165
+627,773
+80% +$40.1M
2018 Q2
29 quarters
GHRS icon
6
GH Research
GHRS
$1.29B
$126M 5.12%
8,827,712
– –
2021 Q2
17 quarters
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$5.17B
$110M 4.44%
1,495,290
-1,266,043
-46% -$80.5M
2023 Q3
8 quarters
XOMA icon
8
DELISTED
Xoma
XOMA
$99.8M 4.05%
2,590,303
– –
2016 Q4
35 quarters
GPCR icon
9
Structure Therapeutics
GPCR
$1.59B
$89.7M 3.64%
3,203,917
+1,432,500
+81% +$28.5M
2023 Q1
10 quarters
KURA icon
10
Kura Oncology
KURA
$874M
$76.3M 3.09%
8,617,162
+863,033
+11% +$6.15M
2017 Q3
32 quarters
SEPN icon
11
Septerna Inc
SEPN
$1.7B
$75.5M 3.06%
4,015,790
-380,334
-9% -$4.99M
2024 Q4
3 quarters
PVLA icon
12
Palvella Therapeutics
PVLA
$1.85B
$72.8M 2.95%
1,161,249
+464,694
+67% +$20.7M
2016 Q2
37 quarters
NKTR icon
13
Nektar Therapeutics
NKTR
$1.29B
$72.6M 2.94%
+1,276,595
New +$42.3M
2025 Q3
0 quarters
ZYME icon
14
Zymeworks
ZYME
$1.8B
$67.3M 2.73%
3,938,641
-370,294
-9% -$5.3M
2022 Q4
11 quarters
AXSM icon
15
Axsome Therapeutics
AXSM
$8.19B
$59.1M 2.4%
486,757
-1,203,464
-71% -$136M
2024 Q2
5 quarters
ACIU icon
16
AC Immune
ACIU
$239M
$57.3M 2.32%
19,822,436
– –
2018 Q3
28 quarters
IMCR icon
17
Immunocore
IMCR
$1.43B
$57.2M 2.32%
1,574,288
+550,000
+54% +$18.7M
2025 Q2
1 quarter
OLMA icon
18
Olema Pharmaceuticals
OLMA
$614M
$51.8M 2.1%
5,295,893
– –
2020 Q4
19 quarters
TYRA icon
19
Tyra Biosciences
TYRA
$1.28B
$51.1M 2.07%
3,649,794
-294,400
-7% -$3.36M
2021 Q3
16 quarters
ABVX icon
20
Abivax
ABVX
$7.52B
$47.4M 1.92%
+558,031
New +$34.2M
2025 Q3
0 quarters
GLUE icon
21
Monte Rosa Therapeutics
GLUE
$844M
$41.9M 1.7%
5,660,132
– –
2024 Q4
3 quarters
FDMT icon
22
4D Molecular Therapeutics
FDMT
$683M
$40.2M 1.63%
4,629,289
– –
2020 Q4
19 quarters
STOK icon
23
Stoke Therapeutics
STOK
$1.45B
$38.9M 1.58%
+1,657,096
New +$28.4M
2025 Q3
0 quarters
CGEM icon
24
Cullinan Oncology
CGEM
$907M
$34.1M 1.38%
5,750,683
– –
2021 Q1
18 quarters
CELC icon
25
Celcuity
CELC
$3.09B
$32.5M 1.32%
658,421
-2,807,579
-81% -$112M
2024 Q2
5 quarters
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q3 2025 Portfolio in Review

As of Q3 2025, BVF Inc held 50 positions worth $2.47B, down 12% from $2.8B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

BVF Inc withdrew a net $269M in Q3 2025, closing 4 positions and reducing 9 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $75.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, BVF Inc opened a new position in Nektar Therapeutics worth $72.6M.

  • BVF Inc's largest Q3 2025 buy was Nektar Therapeutics: 1,276,595 shares worth $72.6M.
  • BVF Inc added most to Cidara Therapeutics in Q3 2025, an estimated $40.1M increase.
  • BVF Inc's biggest Q3 2025 reduction was Axsome Therapeutics, cutting an estimated $136M.
  • BVF Inc fully exited Ionis Pharmaceuticals in Q3 2025, selling an estimated $75.6M.
  • BVF Inc's ten largest holdings make up 59% of its $2.47B portfolio in Q3 2025.
  • BVF Inc opened 6 new positions and closed 4 in Q3 2025.
  • BVF Inc's portfolio value fell 12% quarter-over-quarter to $2.47B.

Based on BVF Inc's 13F filing for Q3 2025, filed 14 Nov 2025.